- Active not recruitingPHASE2
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
This study looks at new ways to help patients with stomach or gullet cancer after their regular chemotherapy. It tests if different medicines or close monitoring can keep the cancer under control for longer.
For: Adenocarcinoma of the Oesophagus · Adenocarcinoma of the Gastro-oesophageal Junction · Adenocarcinoma of the StomachUnited Kingdom - Active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
For: Gastric Neoplasms · Gastroesophageal Adenocarcinoma · Esophageal AdenocarcinomaArgentina · Australia · Belgium - RecruitingPHASE2
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
This study looks at new treatments for stomach or food pipe cancer that can be removed by surgery. It aims to see how safe and effective these new drugs or drug combinations are before and after the operation.
For: Gastroesophageal AdenocarcinomaUnited States · Canada · China - AuthorisedPhase II and Phase III (Integrated)
A phase 2 trial of capecitabine for recurrent and/or metastatic salivary duct carcinoma – CAESAR trial
This study is looking at a drug called capecitabine to see how well it works for people with a type of cancer called salivary duct carcinoma that has come back or spread. The main goal is to see if the cancer shrinks or stops growing.
For: Salivary Duct CarcinomaNetherlands - RecruitingPHASE1, PHASE2
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
This study is for people with advanced breast cancer that has grown despite previous treatments. It tests a new combination of targeted radiation therapy and chemotherapy to see if it can stop cancer growth and if it's safe. We're looking at different doses to find the best way to use these treatments.
For: Breast CancerUnited States · Australia · Canada - RecruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
For: Endometrial Cancer · Gastric Cancer · Metastatic Castration-resistant Prostate CancerUnited States · Canada · China - RecruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This study looks at a new drug combination, sacituzumab tirumotecan and pembrolizumab, for a type of breast cancer called triple-negative. It's for patients who had initial treatment but still have some cancer cells after surgery. We want to see if this new combination helps prevent the cancer from coming back better than standard care.
For: Triple-Negative Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
This study looks at a new drug, zolbetuximab, combined with chemotherapy for advanced stomach or food pipe cancer. It aims to see if this combination works better than chemotherapy alone for people with a specific protein in their cancer.
For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer · Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer · Metastatic Gastric Adenocarcinoma or CancerUnited States · Argentina · Canada - RecruitingPHASE3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
This study is looking at new treatments for triple-negative breast cancer that remains after surgery. It compares a new drug combination (sacituzumab govitecan-hziy and pembrolizumab) with standard treatments to see if it's more effective and safe for patients.
For: Triple Negative Breast CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
This study looks at a new drug, trastuzumab deruxtecan, for advanced breast cancer that is HER2-low and hormone receptor positive. We want to see if it works better and is safer than standard chemotherapy for people whose cancer has progressed after other treatments.
For: Advanced or Metastatic Breast CancerUnited States · Argentina · Australia - AuthorisedTherapeutic confirmatory (Phase III)
Efficacy of the use of neoadjuvant with/without hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced colon cancer: A phase III multi-arm, randomized and controlled clinical trial (FOXHIPECT4)
This study is testing different ways to treat advanced colon or upper rectal cancer. It looks at adding a special heated chemotherapy wash to standard treatment during surgery to see if it helps people live longer without the cancer coming back. The aim is to find the best treatment.
Spain - Active not recruitingPHASE3
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has spread and has a specific gene change (BRAF). It compares these new combinations with standard chemotherapy to see which works best for people who haven't had treatment for their spread cancer.
For: NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
This study is for people with advanced HR+/HER2- breast cancer. It compares a new drug, sacituzumab tirumotecan (alone or with pembrolizumab), against standard chemotherapy, to see which treatment best controls the cancer's growth.
For: Breast NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
This study looks at a new treatment for a type of breast cancer that has come back or spread. It combines a drug called pembrolizumab with standard chemotherapy to see if it works better than chemotherapy alone for HR+/HER2- breast cancer.
For: Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE2
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
This study is for people with HER2-positive breast cancer that has spread. It's testing a new drug called evorpacept alongside standard treatments like trastuzumab and chemotherapy. Researchers want to see if this combination is safe and helps people whose cancer has grown despite previous treatments.
For: Breast Cancer, MetastaticUnited States · Canada · France - Active not recruitingPHASE3
Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma
This study compares two ways to shrink rectal cancer before surgery or to help avoid surgery altogether. It looks at how adding a boost of radiation, either standard or a special type called CXB, affects the chance of saving the rectum and anus.
For: Rectal NeoplasmsFrance · Switzerland · United Kingdom - RecruitingPHASE3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
This study looks at new drug combinations for stomach (gastric) or food pipe (GEJ) cancer that has a specific marker called HER2. It compares different treatment mixes to see which works best and is safest for advanced cancer.
For: HER2-positive Gastric Cancer · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
This study looks at two drug combinations for HER2-positive breast cancer that has spread. It compares a new drug, zanidatamab, with a standard drug, trastuzumab, both given with chemotherapy, to see which works best and is safest after previous treatments haven't worked.
For: Metastatic HER2-positive Breast CancerUnited States · Australia · Austria - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
This study looks for better ways to treat early-stage, high-risk breast cancer. It tests a new targeted therapy, sacituzumab tirumotecan, with other standard treatments to see if it reduces cancer and helps people live longer without the cancer returning.
For: Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
This study looks at a new drug, zolbetuximab, alongside usual treatments for stomach or gullet cancer that has spread or can't be removed. It aims to see if this combination helps people live longer by targeting specific proteins on cancer cells.
For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer · Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer · Metastatic Gastric Adenocarcinoma or CancerUnited States · Australia · Belgium - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - RecruitingPHASE3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
This study is testing new combinations of medicines (sonesitatug vedotin, rilvegostomig, and capecitabine) for advanced stomach, gastroesophageal junction, or oesophageal cancers. It aims to see how well they work and if they are safe for people whose cancer has a specific marker called Claudin18.2.
For: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Esophageal CancerUnited States · Australia · Austria - RecruitingPHASE3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
This study looks at a new drug, patritumab deruxtecan, for a certain type of advanced breast cancer. It aims to see if this new treatment helps people live longer or stops cancer from growing compared to standard treatments like chemotherapy.
For: Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
This study looks at a new drug, zongertinib, for different HER2+ cancers that have spread. Researchers want to find the best dose, alone and with other treatments, to see if it can shrink tumours.
For: Metastatic Breast Cancer · Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction AdenocarcinomaUnited States · Belgium · China - Active not recruitingPHASE3
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
This study is looking at a new medicine called Dato-DXd for advanced triple-negative breast cancer. It compares Dato-DXd with standard chemotherapy in patients who cannot have a specific type of immunotherapy. The aim is to see if Dato-DXd is better at shrinking tumours and helping people live longer.
For: Breast CancerUnited States · Argentina · Belgium - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
For: Locally Advanced or Unresectable Metastatic Breast Cancer · Stage IV Breast CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study looks at a new way to give a cancer drug called tislelizumab for advanced stomach cancer. We're comparing injections under the skin to drips into a vein, alongside usual chemotherapy. We want to see if the injection works just as well and is easier for patients.
For: Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Austria - Active not recruitingPHASE3
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
This study tests a new drug, Dato-DXd, for advanced breast cancer. It compares Dato-DXd to standard chemotherapy in women whose cancer is HR-positive and HER2-negative and has already been treated with other chemotherapy. Researchers want to see if Dato-DXd works better.
For: Breast CancerUnited States · Argentina · Belgium - Active not recruitingPHASE3
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
This study is testing a new combination of medicines with chemotherapy for some upper gut cancers that have spread and can't be removed by surgery. It aims to see if the new combination works better than current treatments.
For: Advanced Upper Gastrointestinal Tract AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
This study is testing a new combination treatment for advanced bowel cancer. It compares a new medicine (S95005) with an existing one (capecitabine), both given with bevacizumab. The aim is to see if the new combination works better for patients who can't have intensive chemotherapy.
For: Metastatic Colorectal CancerArgentina · Australia · Austria - RecruitingPHASE1, PHASE2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
This study looks at new drug combinations with a medicine called pembrolizumab and chemotherapy for advanced stomach or oesophageal cancer that can't be removed by surgery. It's in early stages (Phase 1/2) and aims to find safe doses and see how well the treatments work.
For: Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal NeoplasmsUnited States · Brazil · Chile - Active not recruitingPHASE3
Detect V / CHEVENDO (Chemo vs. Endo)
This study compares different treatments for advanced breast cancer that has spread. It aims to see if a combination of targeted therapies and hormone therapy works better than targeted therapies and chemotherapy, while also keeping quality of life high.
For: Metastatic Breast CancerGermany - Active not recruitingPHASE3
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
This study looks at new drug combinations for stage I-III triple-negative breast cancer that hasn't fully responded to initial treatment. It compares Dato-DXd with or without Durvalumab against standard treatments to see if they're more effective and safe.
For: Breast CancerUnited States · Belgium · Brazil - Active not recruitingPHASE3
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
This study is for people who have had surgery for bile duct cancer. It's testing a new medicine called rilvegostomig with chemotherapy, to see if it stops the cancer from coming back. It compares the new medicine to a dummy pill.
For: Biliary Tract CancerUnited States · Australia · Belgium - RecruitingPHASE3
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
This study looks at a new medicine called HLX22, combined with standard treatments, for people newly diagnosed with a certain type of stomach and food pipe cancer. It aims to see how well it works and if it's safe compared to current treatments.
For: Gastroesophageal-junction Cancer · Monoclonal Antibody · Gastric CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
For: Breast CancerUnited States · Australia · Austria - Active not recruitingPHASE2
Study of the Impact of DPD Activity on the Efficacy of Capecitabine
This study looks at how a specific body process, called DPD activity, affects a breast cancer drug called capecitabine. We want to see if checking DPD levels before treatment helps us understand how well the drug will work for women with advanced breast cancer.
For: Breast Neoplasm Malignant FemaleFrance · Monaco - RecruitingPHASE2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study is testing new combinations of medicines for advanced stomach or food pipe cancer that has spread or can't be removed by surgery. It aims to see how well they work and if they are safe. Researchers want to find better ways to treat this type of cancer.
For: Gastric CancerUnited States · China · Japan - Active not recruitingPHASE2, PHASE3
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
This study looks at a blood test (ctDNA) for people with a certain stage of colon cancer after surgery. It helps doctors decide if chemotherapy is helpful by checking for tiny cancer cells left behind that regular scans can't see.
For: Colon Adenocarcinoma · Stage IIA Colon Cancer AJCC v8United States · Canada · Puerto Rico - RecruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
For: Gastric CancerUnited States · Brazil · Canada - RecruitingPHASE2, PHASE3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
This study is looking at a new medicine, RO7771950, for HER2-positive breast cancer that has spread or is hard to remove. It compares RO7771950 with an existing medicine, tucatinib, both given with trastuzumab and capecitabine. The aim is to see if the new medicine works well and is safe.
For: HER2-positive Breast CancerAustralia · Belgium · Canada - Not yet recruitingPHASE3
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
This study looks at new ways to choose chemotherapy after pancreatic cancer surgery to prevent it from returning. Researchers are comparing standard methods with a new genetic test to see which works best for patients in the UK.
For: Pancreatic Ductal AdenocarcinomaGermany · Sweden - Active not recruitingPHASE3
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
This study looks at a new drug, DB-1303/BNT323, for advanced breast cancer that's 'HER2-low' and hormone-positive. It compares the new drug to standard chemotherapy to see if it can stop the cancer from growing for longer.
For: Metastatic Breast CancerUnited States · Argentina · Australia - RecruitingPHASE3
The Sagittarius Trial
This study looks at new ways to treat colon cancer after surgery to stop it coming back. It uses advanced tests called 'liquid biopsies' to help doctors choose the best treatment for each person, aiming for better results and fewer side effects.
For: Colon Cancer Stage II · Colon Cancer Stage IIIGermany · Italy · Spain - Active not recruitingPHASE3
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
This study looks into a new chemotherapy combination (gemcitabine and cisplatin) compared to the usual care (capecitabine or observation) for people with certain bile duct or gallbladder cancers after surgery. We want to see if the new combination works better.
For: Cholangiocarcinoma · Gall Bladder CarcinomaAustralia · Austria · Denmark - Active not recruitingPHASE1
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
This study is testing a new drug, ELVN-002, with existing treatments like trastuzumab and chemotherapy. It's for adults with certain advanced HER2-positive cancers, including breast, stomach, and bowel cancer. The main goal is to find a safe dose and see how well it works.
For: HER2-positive Breast Cancer · HER2-positive Gastric Cancer · HER2 Positive Solid TumorsUnited States · Belgium · France - RecruitingPHASE2, PHASE3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
This study is testing a new drug, iza-bren, for advanced triple-negative breast cancer or ER-low, HER2-negative breast cancer. It compares iza-bren with standard chemotherapy in patients who haven't had previous treatment for advanced disease and can't receive certain immunotherapy drugs.
For: Breast NeoplasmsUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) AIO-KRK-0217.
This study looks at whether a blood test called ctDNA can help doctors decide on treatment for people with stage II bowel cancer. It compares giving chemotherapy based on this test to just watching and waiting, to see which approach leads to better outcomes.
For: colon cancer stage II, rectal cancer stage IIGermany · Austria - Active not recruitingPHASE3
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
This study compares a new breast cancer drug, trastuzumab deruxtecan, with standard treatments. It's for people with HER2-low breast cancer that has spread or can't be removed by surgery and who have already had other treatments.
For: Breast CancerUnited States · Austria · Belgium